Drug intelligence / Profile preview

PRO CAR-501

Development stage: Preclinical
Lead developer: PromiCell Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PRO CAR-501 is an early-stage chimeric antigen receptor (CAR) T-cell therapy being developed by PromiCell Therapeutics. Currently listed as an 'Asset Under Negotiation' in the company's pipeline, specific details regarding its target antigen, therapeutic indication, and development phase remain undisclosed. The asset is part of PromiCell's broader effort to develop innovative cell therapies, which includes both autologous and allogeneic approaches for treating various cancers. Given the naming convention used for other assets in the PromiCell pipeline (such as PRO CAR-201 and PRO CAR-301), it is categorized as a CAR-T cell therapy intended for oncology applications.

Targets

STEAP1 (Six-transmembrane epithelial antigen of prostate 1)

Beyond the preview

Go deeper on PRO CAR-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO CAR-501.

Explore the full profile